ESR1 and breast carcinoma: As lapatinib only weakly suppressed colony formation and poorly induced apoptosis in CTC-ITB-01 cells, our results suggest that direct targeting of HER2 might be not powerful enough to have a therapeutic impact on metastatic ER+/HER2− breast cancer cells (Figure 4C).